Supernus Pharmaceuticals (SUPN) Current Assets (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Current Assets data on file, last reported at $731.6 million in Q1 2026.

• On a quarterly basis, Current Assets rose 6.4% year-over-year to $731.6 million in Q1 2026; TTM through Mar 2026 was $731.6 million, a 6.4% increase from a year earlier, with the FY2025 full-year figure at $644.2 million, down 6.11% from the prior year.
• Current Assets for Q1 2026 stood at $731.6 million, up from $644.2 million in the prior quarter.
• Over the last five years, Current Assets for SUPN reached as high as $883.3 million in Q1 2023 and fell as low as $423.5 million in Q2 2023.
• Historically, Current Assets has averaged $629.3 million across 5 years, with a median of $640.0 million in 2024.
• Across the five-year window, Current Assets soared 55.38% in 2023 and slumped 38.38% in 2024, its largest moves.
• Year by year, Current Assets stood at $734.2 million in 2022, then slumped by 32.83% to $493.1 million in 2023, then soared by 39.13% to $686.1 million in 2024, then retreated by 6.11% to $644.2 million in 2025, then gained by 13.57% to $731.6 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $731.6 million in Q1 2026, $644.2 million in Q4 2025, and $593.9 million in Q3 2025.